DRES-10. DRD5 IS A MODULATOR OF GLIOMA SUSCEPTIBILITY TO DRD2 ANTAGONISM BY ONC201

ONC201 is the first selective antagonist of dopamine receptor D2 (DRD2) and D3 (DRD3) for clinical oncology that has exhibited preliminary clinical activity in high grade gliomas. We investigated DRD2 dysregulation in glioma and its role in ONC201 efficacy. Investigating CRISPR screens across a spec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Vijay Prabhu, Varun, Madhukar, Neel, Gilvary, Coryandar, Kline, C Leah B, Tarapore, Rohinton, El-Deiry, Wafik, Doherty, Faye, VanEngelenburg, Alexander, Durrant, Jessica, Benes, Cyril, Oster, Wolfgang, Elemento, Olivier, Allen, Joshua
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2018
Schlagworte:
Abstracts
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216484/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.317
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge